Thomas Michael Perone J.D., M.B.A. is the Gen. Counsel, Chief Compliance Officer & Corp. Sec. at Ovid Therapeutics Inc.
As the Gen. Counsel and Chief Compliance Officer & Corp. Sec. of Ovid Therapeutics Inc, the total compensation of Mr A at Ovid Therapeutics Inc is $633,371. There are 5 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.
Mr A is 56, he's been the Gen. Counsel and Chief Compliance Officer & Corp. Sec. of Ovid Therapeutics Inc since . There are 7 older and 8 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
Thomas's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK, NY, 10001.
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan, and Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: